Bio-Techne Corp. paid $250mm cash to acquire privately held molecular pathology firm Advanced Cell Diagnostics Inc. (ACD). The deal could also include up to $75mm in earn-outs. (Aug.)
The deal marks Bio-Techne's foray into the genomics field. ACD develops and sells genomic analysis consumables for its RNA in situ hybridization technology RNAscope. The platform allows for the detection...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?